Cancer immunotherapy: The dark side of PD-1 receptor inhibition.

about

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer.Immuno-Oncology: Emerging Targets and Combination Therapies

P2860

Q52317592-A8B45204-F1F5-4279-8572-C94941565233 Q56889817-5C721DDB-0A33-479F-962C-FF6CE8B913AB

P2860

Cancer immunotherapy: The dark side of PD-1 receptor inhibition.

Item

http://www.wikidata.org/entity/Q49971148

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Cancer immunotherapy: The dark side of PD-1 receptor inhibition.

@en

Cancer immunotherapy: The dark side of PD-1 receptor inhibition.

@nl

type

Item

label

Cancer immunotherapy: The dark side of PD-1 receptor inhibition.

@en

Cancer immunotherapy: The dark side of PD-1 receptor inhibition.

@nl

prefLabel

Cancer immunotherapy: The dark side of PD-1 receptor inhibition.

@en

Cancer immunotherapy: The dark side of PD-1 receptor inhibition.

@nl

P1476

Cancer immunotherapy: The dark side of PD-1 receptor inhibition.

@en

P2093

Aya Ludin

http://www.w3.org/2001/XMLSchema#string

Leonard I Zon

http://www.w3.org/2001/XMLSchema#string

P2860

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

Serine-threonine kinases in TCR signaling.

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.

The emerging role of immune checkpoint inhibition in malignant lymphoma.

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.

P2888

nature24759

P304

41-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE24759

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

7683

http://www.w3.org/2001/XMLSchema#string

P478

552

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092693820

http://www.w3.org/2001/XMLSchema#string

P698

29143822

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

6136420

http://www.w3.org/2001/XMLSchema#string

Cancer immunotherapy: The dark side of PD-1 receptor inhibition.

about

P2860

P2860

Cancer immunotherapy: The dark side of PD-1 receptor inhibition.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698

P921

P932